Genprex GNPX Q1 2026 Earnings Continued RD Investment as Gene Therapy Pipeline Progresses APYX Q1 2026 Earnings EPS Beats Expectations Despite Revenue Uncertainty Fate Therapeutics Q1 2026 Earnings EPS Beat Drives Stock Uptick Amid Continued Pipeline Progress FITBM Q1 2026 Earnings Strong EPS Surprise of 3509 Outperforms Estimates RCON Q4 2025 Earnings EPS Surprise Beats Estimates Amid Revenue Uncertainty NHI Q1 2026 Earnings EPS Misses Estimates Amidst Strategic Portfolio Shift